Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Trial details
- Registry ID
- NCT07007312
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Cytosar-U; Tarabine PFS; cytosine arabinoside (ara-C)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312 | KURA | Phase 3 | Recruiting | 2031-11Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |